391 related articles for article (PubMed ID: 22520346)
1. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
2. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis.
Curatolo P; Bombardieri R; Jozwiak S
Lancet; 2008 Aug; 372(9639):657-68. PubMed ID: 18722871
[TBL] [Abstract][Full Text] [Related]
4. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.
Roth J; Roach ES; Bartels U; Jóźwiak S; Koenig MK; Weiner HL; Franz DN; Wang HZ
Pediatr Neurol; 2013 Dec; 49(6):439-44. PubMed ID: 24138953
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis complex: balancing proliferation and survival.
Tomasoni R; Mondino A
Biochem Soc Trans; 2011 Apr; 39(2):466-71. PubMed ID: 21428921
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of tuberous sclerosis in children].
Riquet A; Cuisset JM; Cuvellier JC; Joriot S; Petit F; Vallée L
Arch Pediatr; 2010 Sep; 17(9):1338-45. PubMed ID: 20709508
[TBL] [Abstract][Full Text] [Related]
10. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
11. Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture.
Roach ES
Pediatr Neurol; 2016 Oct; 63():6-22. PubMed ID: 27543366
[TBL] [Abstract][Full Text] [Related]
12. [Tuberous sclerosis].
Metsähonkala L; Valanne L; Anttonen AK
Duodecim; 2013; 129(17):1779-87. PubMed ID: 24159711
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex: Recent advances in manifestations and therapy.
Wataya-Kaneda M; Uemura M; Fujita K; Hirata H; Osuga K; Kagitani-Shimono K; Nonomura N;
Int J Urol; 2017 Sep; 24(9):681-691. PubMed ID: 28667702
[TBL] [Abstract][Full Text] [Related]
14. Dissociate expression of tuberous sclerosis complex 1 product hamartin in a skin and pulmonary lesion of a tuberous sclerosis complex.
Wataya-Kaneda M; Katayama I
Hum Pathol; 2009 Mar; 40(3):430-4. PubMed ID: 18835623
[TBL] [Abstract][Full Text] [Related]
15. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
16. [Care continuity for patients with tuberous sclerosis complex (TSC) during transition from childhood to adulthood].
Kiyoko S; Hitoshi O
Nihon Rinsho; 2010 Jan; 68(1):136-40. PubMed ID: 20077806
[TBL] [Abstract][Full Text] [Related]
17. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
Lee L; Sudentas P; Dabora SL
Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
[TBL] [Abstract][Full Text] [Related]
18. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
20. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Rosner M; Freilinger A; Hengstschläger M
Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
